Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Selicrelumab |
Trade Name | |
Synonyms | RO7009789|CP 870,893 |
Drug Descriptions |
Selicrelumab (RO7009789) is a monoclonal antibody to TNFRSF5 (CD40), which mimics the binding of the ligand, CD40LG (CD40L), to stimulate proliferation of T-cells and enhance an anti-tumor response (PMID: 26386124). |
DrugClasses | CD40 Antibody 14 |
CAS Registry Number | 1622140-49-1 |
NCIT ID | C119740 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Bevacizumab + Selicrelumab | Atezolizumab Bevacizumab Selicrelumab | 0 | 1 |
Atezolizumab + Gemcitabine + Nab-paclitaxel + Selicrelumab | Atezolizumab Gemcitabine Nab-paclitaxel Selicrelumab | 0 | 0 |
Bevacizumab + Selicrelumab | Bevacizumab Selicrelumab | 0 | 1 |
Emactuzumab + Selicrelumab | Emactuzumab Selicrelumab | 0 | 1 |
RO5520985 + Selicrelumab | RO5520985 Selicrelumab | 0 | 1 |
Selicrelumab | Selicrelumab | 0 | 1 |